A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With SCLC
← catalyst calendarNCT06745323 · readout in 995 d
Sponsored by Amgen (industry) · AMGN — their whole pipeline →.
Phase
Phase 2
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
252actual
Sites
78
Countries
Argentina, Australia, Belgium +13
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-02-26 | actual | When the study began enrolling |
| Primary completion | 2029-05-10 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2029-05-10 | estimated | The whole study's end, after follow-up |
| First posted | 2024-12-20 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-17 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Small Cell Lung Cancer (SCLC)
Intervention
- Drug: Tarlatamab — also filed as AMG 757
Primary outcomes
what the primary-completion date above is the date OFProportion of participants with confirmed objective response to Tarlatamab
measured Approximately 52 Months
Proportion of participants with complete response to Tarlatamab
measured Approximately 52 Months
Proportion of participants with partial response to Tarlatamab
measured Approximately 52 Months
Permalink · AMGN's whole pipeline · Catalyst calendar · Every registered study · What changed